Brief: CSL To Launch Clinical Trials To Evaluate Enhanced Plasma Manufacturing
29/07/2026 24:28
BRIEF-CSL To Launch Clinical Trials To Evaluate Enhanced Plasma Manufacturing July 29 (Reuters) - CSL Ltd CSL.AX:
TO LAUNCH CLINICAL TRIALS TO EVALUATE ENHANCED PLASMA MANUFACTURING
WILL UNDERTAKE CLINICAL TRIAL WORK TO CONFIRM EFFICACY AND SAFETY OF IMMUNOGLOBULIN MANUFACTURED USING ITS NEXT GENERATION HORIZON 2 PROCESS
HORIZON 2 TECHNOLOGY ENABLES GREATER IMMUNOGLOBULIN PRODUCTION
TO SEEK FDA AND EMA APPROVAL FOR HORIZON 2
TO LAUNCH CLINICAL TRIALS FOR HORIZON 2 IMMUNOGLOBULIN PROCESS
TO COMMENCE HORIZON 2 CLINICAL ACTIVITIES IN MID-2027
Further company coverage: CSL.AX
((Reuters.Briefs@thomsonreuters.com;))